跳至主要内容
临床试验/NCT04242420
NCT04242420招募中不适用

Impact of Connexin 37, Connexin 43 on Clinical Disease Phenotype in Delta F508 Homozygous Patients With Cystic Fibrosis (CF) (CF-Modifier)

University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)3 个研究点 分布在 2 个国家目标入组 300 人开始时间: 2002年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
300
试验地点
3
主要终点
Survival to end stage lung disease

研究概览

简要总结

Background: There is wide variety in lung disease phenotype for the delta F508 (homozygous) genotype. A leukocyte driven inflammation is most important for the pathogenesis of pulmonary disease in CF. Blood cytokines correlate negatively with pulmonary function in delta F508 homozygous patients. Gap junction proteins might be of importance for the influx of blood cells into the lung and may influence the course of pulmonary inflammation. A primary analysis (Horn et al. 2020) has shown that GJA4 variants (rs41266431) are linked to more severe disease in CF. This is very similar to variants of MBL.

Aims: To assess the relationship between gap junction proteins alpha 1 (GJA1/Connexin 43) and alpha 4 (GJA4/connexin 37) genotypes and clinical disease phenotype. Moreover are GJA4 variants in terms of clinical phenotype independent of MBL variants.

Methods:Patients homozygous for delta F508 get recruited from the CF centres of Bonn, Frankfurt and Amsterdam. Sequence analysis is performed for connexin 43 and 37 and MBL genotypes. Clinical disease is assessed longitudinally over 3 years by pulmonary function tests (FEV1 (forced expiratory volume in one second), FVC (=(forced vital capacity), FEF75 % (Forced expiratory flow at 75% of the pulmonary volume) pred), BMI (percentiles), P. aeruginosa colonization, diabetes mellitus and survival to end-stage CF lung disease (death or lung transplantation).

详细描述

Progressive pulmonary destruction is the major cause of morbidity and mortality in human subjects with cystic fibrosis. Many studies could not find an association between delta F 508 and severity of pulmonary disease . The most important factor in CF lung disease is an inflammation driven by leukocytes and cytokines. The investigators have provided evidence in former studies that cytokines (Interleukin-8 (IL-8), tumour necrosis factor (TNF) alpha, Lipopolysaccahride binding protein (LBP), transforming growth factor (TGF) ß)measured in blood correlate negatively with lung function in delta 508 homozygous patients.

The question arises, what other factors influence recruitment of proinflammatory leukocytes from blood capillaries into the lung .

Connexins are a family of transmembrane proteins, which oligomerize into hexameric structures to form a hemichannel (connexon) and ultimately pair with a partner hemichannel in an adjacent cell to form gap junction intercellular communication channels (GJIC) . There is evidence of expression of connexin 37 (=gap junction protein A4 (GJA4)) on macrophages in humans. Moreover there is evidence of expression of connexin 37 on vascular endothelia in humans . Connexin 37 is expressed on human neutrophils . Pulmonary disease in CF is dominated by a leukocyte driven inflammation. GAP junction proteins might be of importance for the influx of blood cells into the lung. In this regard, the hypothesis was that Cx37 or Cx43 genotypes have an impact on clinical disease phenotype in CF patients homozygous for delta F508. The first analysis (Horn et al 2020) has shown a clinical phenotype linked to the GJA4 genotype is very similar to MBL variants. In this regard the question arises whether there is a link between the MBL variant alleles and the GJA4 variants. Moreover some TGFbeta genotypes are linked to certain pulmonary phenotypes. So we are looking for interactions between Cx37 and TGFbeta genotypes and their impact on the clinical phenotype as well.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
6 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Homozygosity for delta F 508

排除标准

  • treatment with systemic steroids 14 days preceding this trial, participation in another study within the past 30 days, treatment with Orkambi or status after lung transplantation (for assessment of all parameters except survival).

结局指标

主要结局

Survival to end stage lung disease

时间窗: through study completion, on average 27 years

End stage lung disease: Death or lung transplantation

Lung function parameters: FEF75

时间窗: 3 years

Best FEF75 value in % predicted of the year according to German registry according to Global lung initiative (GLI)

Lung function parameter: FEV1

时间窗: 3 years

Best FEV1 value in % predicted of the year according to German registry according to Global lung initiative (GLI)

Lung function parameters: FVC

时间窗: 3 years

Best FVC value in % predicted of the year according to German registry according to Global lung initiative (GLI)

次要结局

  • Inflammatory markers in sputum(through study completion, an average of 3 year)
  • Interleukin-8 in sputum(through study completion, an average of 3 year)
  • Interleukin-8 in blood(through study completion, an average of 3 year)
  • White blood cell count(through study completion, an average of 3 year)

研究者

发起方
University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)
申办方类型
Other
责任方
Principal Investigator
主要研究者

Sabina Schmitt-Grohe

Principal investigator

University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)

研究点 (3)

Loading locations...

相似试验